Key facts
- It has raised $4.0M; the latest was Seed Round ($4.0M) in Mar 2026.
- Notable investors include UK Innovation & Science Seed Fund, Northern Gritstone, Advanced Research + Invention Agency, Northern Universities Ventures Fund, The University of Manchester.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cytotrait
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytotrait are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytotrait
Developer of organelle-targeted gene editing technology designed to enable crop trait engineering and agricultural improvement. The company offers a proprietary approach that edits chloroplast and mitochondrial genomes to achieve homoplasmy with compartmentalized, high-level expression rapidly, reduces transgene phytotoxicity, simplifies backcrossing and trait stacking, strengthens genetic containment, and follows a clearer regulatory path with potential carbon savings, enabling seed companies, crop breeders, and agri-biotech firms to enhance yield, resilience, pest and disease resistance, and hybrid production efficiency.
- Sector
- Healthcare
- HQ
- Manchester, United Kingdom
- Founded
- 2023
- Employees
- 5
- Website
- cytotrait.com/
- Ownership
- Privately Held (backing)
Cytotrait doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytotrait shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytotrait in its N-PORT filings yet. We sweep new filings monthly.